AbbVie Files Second Suit Against Alvotech For Patent Infringement Under the BPCIA

Goodwin
Contact

Goodwin

On May 28, AbbVie brought a second action in the Northern District of Illinois for patent infringement against Alvotech hf. under the BPCIA in connection with Alvotech’s proposed biosimilar version of HUMIRA® (adalimumab). AbbVie’s first action was brought in the Northern District of Illinois on April 27, 2021. We previously reported on Alvotech’s complaint (Alvotech USA and Alvotech hf.) brought in the Eastern District of Virginia on May 11, 2021 filing a declaratory judgment action on four of 62 patents asserted against them by AbbVie.

In this second action, AbbVie argues that Alvotech hf.’s notice of commercial marketing provided the same day it filed a declaratory judgment in the Eastern District of Virginia “indicates that Alvotech may attempt to market its biosimilar version of HUMIRA® at-risk before resolution of AbbVie’s related patent infringement action in this District,” and therefore, under the BPCIA “triggers this declaratory judgment action so AbbVie can enforce the 58 patents that Alvotech declined to litigate in both the related action in this District and its improper declaratory judgment action in the Eastern District of Virginia.”

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.